Hoon DSB - Search Results

1

Genetic Variants in Immune Related Genes as Predictors of Responsiveness to BCG Immunotherapy in Metastatic Melanoma Patients.

Ramos RI, Shaw MA, Foshag L, Stern SL, Rahimzadeh N, Elashoff D, Hoon DSB. Ramos RI, et al. Among authors: hoon dsb. Cancers (Basel). 2020 Dec 30;13(1):91. doi: 10.3390/cancers13010091. Cancers (Basel). 2020. PMID: 33396862 Free PMC article.

2

Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin 4.

Morisaki T, Yuzuki DH, Lin RT, Foshag LJ, Morton DL, Hoon DS. Morisaki T, et al. Cancer Res. 1992 Nov 1;52(21):6059-65. Cancer Res. 1992. PMID: 1394231

3

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, et al. Morton DL, et al. Ann Surg. 1992 Oct;216(4):463-82. doi: 10.1097/00000658-199210000-00010. Ann Surg. 1992. PMID: 1417196 Free PMC article. Clinical Trial.

4

Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A.

Hayashi Y, Hoon DS, Park MS, Terasaki PI, Foshag LJ, Morton DL. Hayashi Y, et al. Cell Immunol. 1992 Feb;139(2):411-25. doi: 10.1016/0008-8749(92)90082-z. Cell Immunol. 1992. PMID: 1733512

5

Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide.

Hoon DS, Foshag LJ, Nizze AS, Bohman R, Morton DL. Hoon DS, et al. Cancer Res. 1990 Sep 1;50(17):5358-64. Cancer Res. 1990. PMID: 2143687 Clinical Trial.

6

Active specific immunotherapy in malignant melanoma.

Morton DL, Foshag LJ, Nizze JA, Gupta RK, Famatiga E, Hoon DS, Irie RF. Morton DL, et al. Semin Surg Oncol. 1989;5(6):420-5. doi: 10.1002/ssu.2980050608. Semin Surg Oncol. 1989. PMID: 2531908 Review.

7

Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay.

Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, Kuo C, Foshag LJ, Nizze AJ, Morton DL. Hoon DS, et al. J Clin Oncol. 1995 Aug;13(8):2109-16. doi: 10.1200/JCO.1995.13.8.2109. J Clin Oncol. 1995. PMID: 7636555 Clinical Trial.

8

Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.

Barth A, Hoon DS, Foshag LJ, Nizze JA, Famatiga E, Okun E, Morton DL. Barth A, et al. Cancer Res. 1994 Jul 1;54(13):3342-5. Cancer Res. 1994. PMID: 8012946

9

Interleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cells.

Hoon DS, Hayashi Y, Morisaki T, Foshag LJ, Morton DL. Hoon DS, et al. Cancer Immunol Immunother. 1993 Nov;37(6):378-84. doi: 10.1007/BF01526794. Cancer Immunol Immunother. 1993. PMID: 8242663 Free PMC article.

10

A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine.

Hayashi Y, Hoon DS, Foshag LJ, Park MS, Terasaki PI, Morton DL. Hayashi Y, et al. Cancer. 1993 Aug 1;72(3):750-9. doi: 10.1002/1097-0142(19930801)72:3<750::aid-cncr2820720319>3.0.co;2-v. Cancer. 1993. PMID: 8334627

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

394 results

Search Page

Filters